Q2 2024 Pacira Biosciences Inc Earnings Call Transcript
Key Points
- Pacira BioSciences Inc (PCRX) reported solid sales across all three of its products, with EXPAREL sales increasing to $136.9 million.
- The company has strengthened its balance sheet and bolstered its leadership team, setting the stage for sustainable top-line growth in 2025 and beyond.
- Pacira BioSciences Inc (PCRX) is preparing for separate Medicare reimbursement for EXPAREL, which is expected to drive utilization in outpatient settings.
- The company has launched a national campaign, 'Make The No Pain Impact,' to drive education and awareness among key stakeholders.
- Pacira BioSciences Inc (PCRX) has made significant progress in its research and development pipeline, including promising interim results from a Phase 1 study of PCRX-201 for knee osteoarthritis.
- The FDA's recent approval of a generic liposomal bupivacaine poses a potential threat to EXPAREL's market share.
- The company is involved in multiple patent infringement lawsuits, which could result in prolonged legal battles and uncertainty.
- EXPAREL's volume growth was largely offset by a shift in vial mix and discounting associated with the launch of the Premier partnership.
- Non-GAAP R&D expenses increased due to start-up activities for registration studies, impacting overall profitability.
- The company faces challenges in achieving broad market adoption and integration of new reimbursement policies, requiring ongoing investment in education and awareness initiatives.
Good day and thank you for standing by. Welcome to the Q2 2024 Pacira BioSciences earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Susan Mesco. Head of Investor Relations. Please go ahead.
Thank you, and good afternoon, everyone. Welcome to today's conference call to discuss our second-quarter 2024 financial results. Joining me are Frank Lee, Chief Executive Officer; Tony Molloy, Chief Legal Counsel; and Charlie Reinhart, Chief Financial Officer. Jonathan Sloane, Chief Medical Officer, is also here for today's question-and-answer session.
Before we begin, let me remind you that this call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties. For information concerning risk factors that could affect the company, please refer to our filings with the SEC,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
